Abivax SA Dismisses Reports of a Potential Takeover by AstraZeneca
Abivax SA, the French biotechnology firm listed on the NYSE Euronext Paris, has formally denied speculation that the company was in exclusive talks with AstraZeneca regarding a possible acquisition. The statements were issued in the wake of multiple French media outlets publishing reports that the pharmaceutical giant had engaged in confidential discussions with Abivax about a potential purchase.
The company’s spokesperson clarified that no exclusive bidding process has taken place, nor has any confidential information been shared with AstraZeneca. Abivax emphasized that it remains focused on its development pipeline, which includes lead candidates such as ABX 464 (an HIV/AIDS sustained viral remission therapy in Phase II), ABX 203 (a therapeutic vaccine for chronic hepatitis B in Phase IIb/III), and ABX 196 (an iNKT cell enhancer that completed Phase I). Additional candidates are under pre‑clinical investigation, notably ABX 220 for dengue fever and ABX 544 for Ebola.
Despite the dismissal of the takeover rumors, the stock price reacted sharply to the news. Trading volume increased as investors responded to the clarification, and the share price experienced a temporary pullback following the announcement. The market’s reaction underscores the sensitivity of Abivax’s valuation to speculation about strategic partnerships or ownership changes, particularly given the company’s negative price‑earnings ratio of –32.78 and the volatility of its share price over the past year.
Abivax maintains that it is open to discussions with potential partners that could accelerate the development and commercialization of its therapeutic candidates, but it has stated that any such negotiations would be conducted in a transparent and non‑exclusive manner. The company continues to pursue its pipeline across multiple infectious diseases, targeting markets in Asia and Latin America, while preserving its independent operations and strategic autonomy.
